98%
921
2 minutes
20
Parkinson's Disease (PD) patients undergoing subthalamic nucleus deep brain stimulation (STN-DBS) therapy can reduce levodopa equivalent daily dose (LEDD) by approximately 50 %, leading to less symptoms of dyskinesia. The underlying mechanisms contributing to this reduction remain unclear, but studies posit that STN-DBS may increase striatal dopamine levels by exciting remaining dopaminergic cells in the substantia nigra pars compacta (SNc). Yet, no direct evidence has shown how SNc neuronal activity responds during STN-DBS in PD. Here, we use a hemiparkinsonian rat model of PD and employ in vivo electrophysiology to examine the effects of STN-DBS on SNc neuronal spiking activity. We found that 43 % of SNc neurons in naïve rats reduced their spiking frequency to 29.8 ± 18.5 % of baseline (p = 0.010). In hemiparkinsonian rats, a higher number of SNc neurons (88 % of recorded cells) decreased spiking frequency to 61.6 ± 4.4 % of baseline (p = 0.030). We also noted that 43 % of SNc neurons in naïve rats increased spiking frequency from 0.2 ± 0.0 Hz at baseline to 1.8 ± 0.3 Hz during stimulation, but only 1 SNc neuron from 1 hemiparkinsonian rat increased its spiking frequency by 12 % during STN-DBS. Overall, STN-DBS decreased spike frequency in the majority of recorded SNc neurons in a rat model of PD. Less homogenous responsiveness in directionality in SNc neurons during STN-DBS was seen in naive rats. Plausibly, poly-synaptic network signaling from STN-DBS may underlie these changes in SNc spike frequencies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neulet.2020.135443 | DOI Listing |
The end-stage pathology of Parkinson's disease (PD) involves the loss of dopamine-producing neurons in the substantia nigra pars compacta (SNc). However, synaptic deregulation of these neurons begins much earlier. Understanding the mechanisms behind synaptic deficits is crucial for early therapeutic intervention, yet these remain largely unknown.
View Article and Find Full Text PDFElife
August 2025
Gladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, United States.
Parkinson's disease (PD) is characterized by the death of substantia nigra pars compacta (SNc) dopamine (DA) neurons, but the pathophysiological mechanisms that precede and drive their death remain unknown. The activity of DA neurons is likely altered in PD, but we understand little about if or how chronic changes in activity may contribute to degeneration. To address this question, we developed a chemogenetic (DREADD) mouse model to chronically increase DA neuron activity and confirmed this increase using ex vivo electrophysiology.
View Article and Find Full Text PDFElife
August 2025
Interdisciplinary Program in Neuroscience, Georgetown University, Washington DC, United States.
The canonical basal ganglia model predicts that the substantia nigra (SNr) will inhibit locomotion and the globus pallidus (GPe) will enhance it. In mice, we use in vivo optogenetics to show that the GPe exerts non-canonical effects on locomotion while the SNr has no gross motor impact through inhibition of the pedunculopontine nucleus (PPN). We show that these structures mediate opposing effects on reward and that activation of (SNc) dopaminergic axons in the PPN is rewarding.
View Article and Find Full Text PDFSci Rep
August 2025
Faculty of Engineering and Quantity Surviving, INTI International University Colleges, Nilai, Malaysia.
Parkinson's disease (PD) is one of the well-known neurodegenerative diseases. The main reason is the death of dopaminergic neurons that release dopamine in the brain region known as the Substantia Nigra pars Compacta (SNc). In this study, we developed a mathematical model of Parkinson's disease incorporating a fractal-fractional operator with the Mittag-Leffler kernel to capture the complex, memory-dependent dynamics of the disease.
View Article and Find Full Text PDFGen Comp Endocrinol
August 2025
Department of Biology, University of Naples "Federico II", 80126 Naples, Italy; National Institute of Biostructures and Biosystems (INBB), 00136 Rome, Italy.
The catecolaminergic system, which uses dopamine, noradrenaline and adrenaline as neurotransmitters, originates in the brainstem nuclei and spreads widely throughout the central nervous system (CNS). Although there are data indicating that interactions between the catecolaminergic systems of the nervous system and hypothalamic-pituitary-thyroid axis do indeed take place and may be of physiological and clinical relevance, such interactions are far from being clarified. In this paper, we studied the hypothalamic-pituitary-thyroid axis responses in lizards treated with adrenaline, noradrenaline and dopamine respectively.
View Article and Find Full Text PDF